The Landscape of HER2-Low Metastatic Breast Cancer: Insights from AGMT MBC-Registry

What is the aim of the study conducted by Gampenrieder et al. (2021)?

What do HER2-low breast cancer tumors refer to?

Aim of the Study:

The study conducted by Gampenrieder et al. (2021) aimed to investigate the landscape of HER2-low metastatic breast cancer (MBC) using data from the Austrian AGMT MBC-Registry.

Definition of HER2-Low Breast Cancer:

HER2-low breast cancer refers to tumors with low levels of human epidermal growth factor receptor 2 expression.

Exploring HER2-Low Metastatic Breast Cancer

HER2-low metastatic breast cancer is a subtype of breast cancer characterized by low levels of HER2 expression. The study conducted by Gampenrieder et al. (2021) delves into the clinical characteristics, treatment patterns, and outcomes of patients with HER2-low MBC.

The main aim of the study was to gain insights into the epidemiology and real-world management of HER2-low metastatic breast cancer in the Austrian population. By analyzing data from the AGMT MBC-Registry, the researchers aimed to understand the specific features and challenges associated with this subtype of breast cancer.

The findings of the study contribute significantly to the understanding of HER2-low metastatic breast cancer and can have implications for treatment decision-making. This research could potentially lead to the development of tailored therapeutic approaches that cater specifically to patients with HER2-low MBC.